BioSpace News Archive

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that management will participate in three upcoming investor conferences.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that EyePoint Pharmaceuticals’ senior management team will present at the following four upcoming conferences.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced that management will participate in the H.C. Wainwright Annual Global LifeSciences Conference, which is being held virtually from September 13th-15th.

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced that Barry Labinger, CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Chimerix announced that Mike Sherman, Chief Executive Officer of Chimerix and Mike Andriole, Chief Financial and Business Officer of Chimerix, will participate in a pre-recorded fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference that will be made available on Monday, September 13, 2021 at 7:00 a.m. ET.

FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced management is scheduled to present at the Baird 2021 Global Healthcare Conference on Tuesday, September 14 at 5:30 PM E.T.

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, announced the appointment of Thomas Civik to its Board of Directors and as its Chairman.

Company to Present at Morgan Stanley 19 th Annual Global Healthcare Conference on September 10, 2021

Alnylam Pharmaceuticals, Inc. today announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran